Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European Medicines Agency's (EMA) ...
CAMP4 Therapeutics Corporation has an analyst consensus of Strong Buy, with a price target consensus of $8.36, implying a 99.05% upside from current levels. In a report released on June 10, Chardan ...
Join a team that's shaping market access strategies for innovative therapies. Lead cross-functional initiatives to enhance patient access and payer engagement, ensuring commercial success while ...
June 22 () - Nuvectis Pharma said on Monday it had licensed exclusive rights outside China to two experimental drugs from Haisco Pharmaceutical Group, targeting complement-mediated diseases and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results